Literature DB >> 25107562

The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.

Xin Zhao1, Kai-Ping Zhang, Ting Huang, Cai-Chuan Yan, Li-Rong Liu, Qi-Lei Zhu, Feng-Feng Guo, Chen Liu, Bao-Xin Li.   

Abstract

Arsenic trioxide (As2O3) is used to treat acute promyelocytic leukemia. However, the cardiotoxicity of long QT syndrome restricts its clinical application. Previous studies showed that As2O3 can damage the human ether-a-go-go-related gene (hERG) current via disturbing its trafficking to cellular membrane. This study aimed to investigate whether the As2O3-insulted hERG channel can be rescued by resveratrol, a recognized cardioprotective agent. The whole-cell patch clamp technique was used to record the hERG current and action potential duration. Co-immunoprecipitation and Western blot assay were applied to determine the function of hERG-Hsp70/Hsp90 chaperone complexes and the expression alteration of protein-folding-related proteins, respectively. Compared with treatment of As2O3 alone, co-treatment with resveratrol successfully restored the current and surface expression of hERG and obviously shortened action potential duration in guinea pig ventricular myocytes. Further experiments demonstrate that resveratrol relieved As2O3-caused endoplasmic reticulum (ER) stress by restoring the function of hERG-Hsp70/Hsp90 chaperone complexes and downregulating the protein expression of ER chaperone proteins (calnexin and calreticulin) and activating transcription factor 6. In conclusion, resveratrol was able to rescue the trafficking deficiency and relieve the ER stress (ERS). Our findings suggest that resveratrol has a potential effect to alleviate the adverse effect of As2O3 on cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25107562     DOI: 10.1007/s00210-014-1019-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

1.  Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.

Authors:  Xiaoping Wan; Adrienne T Dennis; Carlos Obejero-Paz; Jeffrey L Overholt; Jorge Heredia-Moya; Kenneth L Kirk; Eckhard Ficker
Journal:  J Biol Chem       Date:  2010-11-20       Impact factor: 5.157

2.  The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.

Authors:  Eckhard Ficker; Carlos A Obejero-Paz; Shuxia Zhao; Arthur M Brown
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

Review 3.  Resveratrol in cardiovascular health and disease.

Authors:  Goran Petrovski; Narasimman Gurusamy; Dipak K Das
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

4.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Authors:  G Q Chen; X G Shi; W Tang; S M Xiong; J Zhu; X Cai; Z G Han; J H Ni; G Y Shi; P M Jia; M M Liu; K L He; C Niu; J Ma; P Zhang; T D Zhang; P Paul; T Naoe; K Kitamura; W Miller; S Waxman; Z Y Wang; H de The; S J Chen; Z Chen
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

5.  Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis.

Authors:  Zhi-Yuan Wu; De-Jie Yu; Tuck Wah Soong; Gavin S Dawe; Jin-Song Bian
Journal:  J Biol Chem       Date:  2011-04-27       Impact factor: 5.157

6.  Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.

Authors:  Sridharan Rajamani; Corey L Anderson; Blake D Anson; Craig T January
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

7.  Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo.

Authors:  X-Y Zhao; G-Y Li; Y Liu; L-M Chai; J-X Chen; Y Zhang; Z-M Du; Y-J Lu; B-F Yang
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

Review 8.  Cardiac channelopathies: genetic and molecular mechanisms.

Authors:  Hugues Abriel; Elena V Zaklyazminskaya
Journal:  Gene       Date:  2012-12-22       Impact factor: 3.688

9.  Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Authors:  Eckhard Ficker; Yuri A Kuryshev; Adrienne T Dennis; Carlos Obejero-Paz; Lu Wang; Peter Hawryluk; Barbara A Wible; Arthur M Brown
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

10.  Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?

Authors:  M A G van der Heyden; M E Smits; M A Vos
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more
  4 in total

1.  Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells.

Authors:  Yea Lu Tay; Azimah Amanah; Mohd Ilham Adenan; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

2.  Protective Effect of Resveratrol against Hexavalent Chromium-Induced Genotoxic Damage in Hsd:ICR Male Mice.

Authors:  Tonancy Nicolás-Méndez; Sam Kacew; Alda Rocío Ortiz-Muñiz; Víctor Manuel Mendoza-Núñez; María Del Carmen García-Rodríguez
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

3.  Mechanisms underlying probucol-induced hERG-channel deficiency.

Authors:  Yuan-Qi Shi; Cai-Chuan Yan; Xiao Zhang; Meng Yan; Li-Rong Liu; Huai-Ze Geng; Lin Lv; Bao-Xin Li
Journal:  Drug Des Devel Ther       Date:  2015-07-20       Impact factor: 4.162

4.  Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency.

Authors:  Meng Yan; Kaiping Zhang; Yanhui Shi; Lifang Feng; Lin Lv; Baoxin Li
Journal:  Drug Des Devel Ther       Date:  2015-10-22       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.